Cerulean Pharma (Cambridge, MA) a clinical-stage nanopharmaceutical company focused on non-small cell lung cancer, closed a $15M Series D financing. Participants include Lilly Ventures, Polaris Venture Partners, Venrock, Lux Capital, CVF and Bessemer Venture Partners.